Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2019 09:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

TORONTO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
February 21, 2019 16:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

TORONTO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
December 03, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual Meeting

TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
November 14, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Third Quarter 2018 Financial and Operating Results

Positive clinical update on the intratumoral trial of TTI-621, a CD47 immune checkpoint inhibitor, presented at the 2018 EORTC CLTF meetingPositive clinical update on the intravenous trial of TTI-621...
September 28, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Provide Update on TTI-621 Clinical Programs at Two Scientific Conferences

Data from intralesional trial in mycosis fungoides/Sézary syndrome patients continue to show promise, with rapid reductions in CAILS scores in the majority of patients and preliminary evidence of...
September 27, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Present at Upcoming Investor Conferences

TORONTO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
September 12, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings

Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target ConferenceUpdated data from the TTI-621 intralesional trial in patients with mycosis...
August 30, 2018 09:30 ET | Source: Trillium Therapeutics Inc.

Trillium to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

TORONTO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
August 08, 2018 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Second Quarter 2018 Financial and Operating Results

Increased focus on T cell lymphoma in lead program, TTI-621 Initiated dosing of TTI-622 (SIRPaFc IgG4) in phase 1a/1b clinical trial Recruited Dr. Yaping Shou as Chief Medical OfficerNegotiated...
June 19, 2018 18:30 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement

TORONTO, June 19, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) (“Trillium” or the “Company”), a clinical stage immuno-oncology company developing innovative therapies...